Andro is a scientist with a background in molecular biology and a proven ability to develop innovative products combining genomics, bioinformatics, and the internet. Andro was on the forefront of innovative usage of genetic profiles as an early 23andMe employee, and joined Syapse to lead Product Management after spending time on his own start-up.
Samantha brings a unique skill set to Syapse, with a background in Computer Science, Bioinformatics and a zeal for customer success; she is ideal to lead our Customer Solutions Team. Sam has experience deploying internal software solutions inside a Biotech firm as well as health related applications at Fortune 500 companies prior to joining Syapse.
Sep combines his expertise in the biological sciences with a passion for computing to help create software solutions in healthcare. Perhaps our most versatile employee, Sep is involved in customer prototyping, QA testing and UI/UX development.
Phil is an experienced software developer with experience in bioinformatics, data mining, web applications, and databases. Phil joined Syapse from Stanford, where he was involved in a variety of projects in their Center for Genomics and Personalized Medicine and a contributor to the ENCODE project.
Jeremy has a long history in building server-side solutions for data-rich web applications. He has played a key role in the Semantic Web community, participating on several W3C working groups defining RDF graphs and named graphs, as well as helping develop the Jena Semantic Web framework. He is also a regular contributor to the open-source community.
Mike is an experienced software engineer with a deep history in scalable infrastructure also having performed research in programming languages and parallel computing. After honing his skills at Google and Obama for America, he is now using his talents in large distributed systems development to solve some of the inherent data-wrangling challenges in healthcare.
Ted is a reformed financial technologist, having spent many years on Wall Street building high performing, mission-critical applications for the hedge fund community. He is now focused on enabling our software to connect with many of the rich data sources that exist in the medical world.
Danny is one of our resident scientists with a background in Human Genetics and Statistical Bioinformatics. He has experiences in Python programming and natural language processing. At Syapse, Danny is excited to bring his passions for biology and computing together to help provide technological solutions to biological problems.
Benjamin is a software developer with a strong interest in healthcare. Benjamin began his career by founding a small enterprise consulting service in Knoxville, Tennessee before moving to the West Coast to hone his skills at Google and 23andMe.
Abhi understands the problems clinicians and translational researchers face when integrating molecular and clinical data. He has published in JAMA, Frontiers in Genetics, and The Washington Post on personalized medicine and health IT issues. He is dedicated to implementing solutions that help clinicians and researchers leverage the full power of genomics and traditional clinical data.
Matt leads the DevOps efforts at Syapse, where he is driven by a passion for helping improve the lives of people through appropriate technology. Although trained as an engineering physicist, he has spent the past decade immersed in distributed systems, automation, scalability, and security issues. Matt serves on the board of the Gentoo Foundation.
With a proven track record of seven successful startups including two IPOs in the past 20 years, Palmer has specialized in accelerating the foundation and growth of early-stage companies that span enterprise software, the Internet, ecommerce, and biotech. Palmer was co-founder and founding CEO of Vertica Systems (acquired by HP). Prior to Vertica, Palmer was the senior vice president of operations and CIO for Infinity Pharmaceuticals (NASDAQ: INFI) and has held executive positions at Bowstreet (acquired by IBM), pcOrder.com and Trilogy.
Peter Donnelly is director of the Wellcome Trust Centre for Human Genetics and professor of statistical science at the University of Oxford. His current research focuses on understanding the genetic basis of common human diseases, human demographic history, bacterial evolution and infection, and the mechanisms involved in mammalian recombination. Donnelly played a major role in the HapMap project, and he currently chairs the Wellcome Trust Case Control Consortium (WTCCC) and its successor, WTCCC2, a large international collaboration studying the genetic basis of more than 20 common human diseases and conditions in over 60,000 people. He also leads WGS500, an Oxford collaboration with Illumina to sequence 500 individuals with a range of clinical conditions, to assess the short-term potential for whole-genome sequencing in clinical medicine.
Scott Barclay is a digital health innovator and strategist based in Palo Alto, CA focused on new applications that leverage big data and new forms of communication to both evolve and disrupt the ecosystem's current approach to care. Scott holds or has recently held advisory roles or completed strategic projects with GE Healthymagination, Accenture global digital health labs, Medgle, AgeTak, Doximity, HealthTap, QualcommLife, and Stanford's StartX incubator.
Dave has more than 18 years of leadership experience in delivering enterprise class software and content solutions in life sciences and medicine. Previously he was CTO at WellnessFX and oversaw the development of the visualized personal health dashboard and companion mobile app. Formerly, he was CTO at Tethys, leading commercial operations and information functions in diagnosing those most at risk of developing Type 2 Diabetes. Prior, he built very, very large databases at Roche, Pfizer and Incyte that created clinical trial candidates from data mining, influenza resistance trends in real time, and toxicology guidance from text analytics... David advises a number of Bay Area startups and non-profit foundations.
Dr. Webb joined Celgene - San Diego in September, 2003 as Vice President, Research and retired in June, 2011. Between 1995 and 2003, he held executive management positions in Syrrx, OSI Pharmaceuticals, Cadus Pharmaceutical Corporation, Axiom Biotechnologies, Inc., and Syntex, Inc., developing and leading drug discovery programs focused on inflammation, asthma, cancer and diabetes. Prior to his experience in the biotechnology industry, Dr. Webb was a member of the Department of Cell Biology at the Roche Institute of Molecular Biology from 1973 to 1987 and Adjunct Professor of Human Genetics at Columbia University College of Physicians and Surgeons. He has published over 200 peer-reviewed publications and abstracts and has served on numerous editorial boards in the field of immunology. Dr. Webb received his Ph.D. from Rutgers University and was a Dernham Junior Fellow in Cancer Research at UCSF before joining the Roche Institute.
Mark has worked on biomedical terminology projects for more than 25 years beginning at the University of California San Francisco (UCSF), where he became the lead extramural architect for the National Library of Medicine (NLM) Unified Medical Language System (UMLS) Metathesaurus. While teaching in the computer science department at UC Berkeley, Mark co-founded Apelon, a pioneer in biomedical terminology projects at the National Cancer Institute, Veterans Administration, Department of Defense, and Health and Human Services. Mark is currently Director of Interoperability at eHealthTrust, and is on the staff of the Center for Bioinformatics at the Mount Sinai School of Medicine. Mark has undergraduate and graduate degrees from Dartmouth, and studied in the Ph.D. program in Computer Science at Harvard.